More on Biosecurity
BOSTON, MA — Chairman Mike Gallagher (R-WI), Ranking Member Raja Krishnamoorthi (D-IL), Reps. Darin LaHood (R-IL), Seth Moulton (D-MA), Neal Dunn (R-FL), and Jake Auchincloss (D-MA) of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (CCP) were in Boston yesterday, where they met with leaders of the U.S. biotechnology industry to discuss the Chinese Communist Party threat to U.S. biosecurity and how U.S. companies can better compete on the global stage.
BOSTON, MA — Chairman Mike Gallagher (R-WI), Ranking Member Raja Krishnamoorthi (D-IL), Reps. Darin LaHood (R-IL), Seth Moulton (D-MA), Neal Dunn (R-FL), and Jake Auchincloss (D-MA) of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (CCP) were in Boston yesterday, where they met with leaders of the U.S. biotechnology industry to discuss the Chinese Communist Party threat to U.S. biosecurity and how U.S. companies can better compete on the global stage.
|
|
WASHINGTON, D.C. — Chairman Mike Gallagher (R-WI) and Ranking Member Raja Krishnamoorthi (D-IL) of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party today introduced the BIOSECURE Act, a bill to ensure foreign adversary biotech companies of U.S. national security concern do not gain access to U.S. taxpayer dollars.
Co-leads in the House include Select Committee members Reps. Neal Dunn (R-FL), Seth Moulton (D-MA), and Jake Auchincloss (D-MA), while Sens. Bill Hagerty (R-TN) and Gary Peters (D-MI) Chairman of the Homeland Security and Governmental Affairs Committee, Mitt Romney (R-UT), and Roger Marshall (R-KS) have already introduced corresponding legislation in the Senate.
Chairman Mike Gallagher (R-WI) and Ranking Member Raja Krishnamoorthi (D-IL) of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party today introduced the BIOSECURE act, a bill to ensure foreign adversary biotech companies of U.S. national security concern do not gain access to U.S. taxpayer dollars.